Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643827 | 1.00 | ALDH1A1 (0.34) | ALDH1A1HPGDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1643829 | 1.00 | ALDH1A1 (0.34) | ALDH1A1HPGDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8127649 | 0.74 | HPGD (0.42) | ALDH1A1HPGDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17864286 | 0.73 | SLC6A2 (0.42) | ALDH1A1HPGDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19368279 | 0.71 | CHRM2 (0.35) | ALDH1A1HPGDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16661514 | 0.71 | — | — | |
| SCHEMBL6637228 | 0.68 | NOS3 (0.37) | ALDH1A1HPGDKMT2AMEN1THRB | |
| SCHEMBL6637225 | 0.68 | NOS3 (0.37) | ALDH1A1HPGDKMT2AMEN1THRB | |
| SCHEMBL1646753 | 0.67 | HTR2A (0.44) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6956559 | 0.67 | HTR2C (0.46) | ALDH1A1HPGDCHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4666533-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| EP-1833782-B1 | CYCLOALKYLAMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | claimed |
| US-7411093-B2 | Aminocycloalkanes as DPP-IV inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-08-12 | — | — | US | claimed |
| JP-2008524279-A | — | — | 2008-07-10 | — | — | JP | claimed |
| CN-101084184-A | Cycloalkylamine derivative | HOFFMANN LA ROCHE (CH) | 2007-12-05 | — | — | CN | claimed |
| EP-1833782-A1 | CYCLOALKYLAMINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-19 | — | — | EP | claimed |
| WO-2006066770-A1 | CYCLOALKYLAMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | claimed |
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | US | claimed |
| EP-1833782-B1 | CYCLOALKYLAMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-7411093-B2 | Aminocycloalkanes as DPP-IV inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-08-12 | — | — | US | disclosed |
| CN-101084184-A | Cycloalkylamine derivative | HOFFMANN LA ROCHE (CH) | 2007-12-05 | — | — | CN | disclosed |
| EP-1833782-A1 | CYCLOALKYLAMINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006066770-A1 | CYCLOALKYLAMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | DPP4, DPP7, DPP3 | ALDH1A1 245/4885HPGD 3734/4885SLC6A2 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.